Mineralys Therapeutics Selected for Oral Poster Presentation of Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions

mineralys therapeutics

RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company, announced it has been selected to present the full results from the Target-HTN Phase 2 trial of lorundrostat in individuals with uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) in an oral poster presentation at the 2023 American Heart Association (AHA) Hypertension Scientific Sessions, which is being held in Boston from September 7–10.

Oral Poster Presentation Details:
Poster Title: Aldosterone Synthase Inhibition with Lorundrostat for the Treatment of Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial
Presenter Name: Luke Laffin, M.D., cardiologist, Cleveland Clinic’s Heart, Vascular & Thoracic Institute, and lead investigator of the Target-HTN trial
Presentation Number: 113
Date/Time: Sunday, September 10 at 7:45 a.m. ET
Session Title: 19.C Insight from the Late Breaking Clinical Trials
For more information, please visit https://mineralystx.com.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.

READ:  CMTA Awards $225,483 for Study on Using ASOs to Treat CMT2E